Cagrilintide Bone Density Trial Opens With Semaglutide Comparator

What the cagrilintide bone density trial is testing

ClinicalTrials.gov now lists a Novo Nordisk study, registration number NCT07010432, with a recruiting status and a planned enrollment of 144 participants. The registry describes it as a Phase 1 trial in women after menopause who have obesity, and states that its purpose is to examine how cagrilintide affects bone health during weight loss compared with placebo and with semaglutide.

What makes the listing notable is the framing. Most incretin and amylin trials that reach public attention are organized around weight change or glucose control, with safety measures collected alongside. Here the skeletal question is the point of the study rather than a secondary endpoint buried in an appendix, and the sponsor has built in an active comparator that is already on the market.

According to the registry entry, the study is expected to last about 79 weeks — roughly a year and a half — which is long enough to observe changes that shorter metabolic studies would miss. Trial registrations describe design and intent, not results; nothing in the posting reports outcomes, and none are available yet.

What is cagrilintide, and what is CagriSema?

Cagrilintide is a long-acting analogue of amylin, a hormone co-secreted with insulin by the pancreas that acts on the brain to signal fullness and slow gastric emptying. It works through a different receptor system than the glucagon-like peptide-1 (GLP-1) receptor agonists that dominate the obesity field, which is why developers have been interested in pairing the two rather than choosing between them.

CagriSema is that pairing: cagrilintide combined with semaglutide, the GLP-1 receptor agonist marketed as Ozempic for type 2 diabetes and Wegovy for weight management. The ClinicalTrials.gov listing for NCT07010432 is explicit that cagrilintide and CagriSema are new medications under development and cannot yet be prescribed, while semaglutide is already approved for overweight and obesity.

That distinction matters for reading the trial. Semaglutide is not in the study as a treatment being tested; it is there as a benchmark, a drug whose weight-loss effect is well characterized, against which the sponsor can measure what an amylin analogue does to bone during a comparable period of weight reduction.

Because semaglutide appears in this trial as the active comparator, readers already on it may find the semaglutide dosage calculator useful for keeping their own records consistent with what a provider prescribed.

A recent review of GLP-1 receptor and melanocortin-4 receptor agonists in obesity and type 2 diabetes describes an expanding set of mechanisms moving through clinical development. a recent review of GLP-1 receptor and melanocortin-4 receptor agonists.

Why bone loss during weight loss is being studied at all

The rationale stated in the registry is that a decline in bone mass is associated with weight loss, and the study asks whether cagrilintide can reduce that decline. This is the sponsor's stated hypothesis, not an established finding about any of the drugs involved, and the trial exists precisely because the answer is not known.

Bone has long been a question in obesity medicine generally, because losing a substantial amount of body mass changes mechanical loading, hormonal signaling and nutrient intake at the same time. Postmenopausal women are a logical population in which to look, since bone turnover in that group is already a clinical concern independent of any weight intervention.

Amylin signaling has drawn interest here because the hormone family has been studied in bone biology as well as appetite regulation. Whether that translates into a measurable protective effect in humans undergoing pharmacologic weight loss is exactly what a 144-person, placebo-controlled Phase 1 study is positioned to start answering.

If skeletal and musculoskeletal complaints become a more common clinic topic, dated side-effect logging is more useful to a provider than a recollection assembled months later.

How the four-arm design works

Participants are randomly assigned — the registry says allocation is decided by chance — to one of four groups: cagrilintide alone, semaglutide alone, CagriSema, or placebo, described in the listing as a dummy treatment with no active substance. PeptideWiz does not report dosing amounts or schedules, and the public registry summary does not present them in a form worth relaying.

A four-arm structure lets investigators separate contributions that would otherwise be confounded. If CagriSema and semaglutide produce similar weight change but differ on bone measures, the difference points to the amylin component. If cagrilintide alone behaves differently from placebo on bone while producing less weight change, that separates drug effect from weight effect.

Phase 1 designation signals that this is early-stage human research focused on safety, tolerability and mechanism rather than a registration trial intended to support approval. Results from a study of this size can shape which endpoints later, larger trials choose to measure, but they do not settle clinical practice.

Trial arms and personal regimens are not the same thing, and our glossary entry on what a protocol is explains the distinction in the terms used across this site.

A second CagriSema study compares the combination with dieting

Alongside the bone study, ClinicalTrials.gov lists NCT07184086, another Novo Nordisk Phase 1 trial, with a status of active and not recruiting and an enrollment of 80 participants. Its stated aim is to look at how CagriSema influences metabolism — described in the listing as the process by which food is used to supply energy — compared with a calorie-reduced weight-loss diet.

The registry describes a two-part structure: in the first part, participants are assigned by chance either to CagriSema or to the diet, and in the second part all participants receive CagriSema. The study is expected to last about a year and a half, and the listing notes, as such listings routinely do, that the investigational medicine may have side effects.

Taken together, the two registrations suggest a deliberate effort to characterize what pharmacologic weight loss does to the body beyond the number on the scale — bone in one study, energy metabolism in the other, each with a non-drug or already-approved reference point built in.

According to the trial registration for NCT07010432, the Phase 1 study is recruiting 144 postmenopausal women with obesity and randomly assigns them to cagrilintide, semaglutide, CagriSema or placebo over roughly 79 weeks.

What is still unresolved

No outcome data exist from either study. One trial is still enrolling and the other has stopped enrolling but has not reported, so any claim about whether cagrilintide protects bone or how CagriSema compares with dieting on metabolic measures would be speculation. Registry entries are also revised over time; status, enrollment and completion dates on ClinicalTrials.gov can change after posting.

The population in the bone study is narrow by design — postmenopausal women with obesity — which strengthens the signal the investigators are hunting for and limits how far the finding could be generalized. Whether results would extend to men, to younger women, or to people using a GLP-1 medication for diabetes rather than weight management is not something a study of this shape can address.

There is also the broader pipeline context. Reviews of the field, including a recent survey of GLP-1 receptor and melanocortin-4 receptor agonists in obesity and type 2 diabetes, describe an expanding set of mechanisms moving through development, and combination products raise more questions about downstream physiology than single agents do.

A second Novo Nordisk registration, NCT07184086, is listed as active and not recruiting with 80 participants and compares CagriSema against a calorie-reduced diet for effects on metabolism. a second Novo Nordisk registration.